Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

Juan W. Valle, Harpreet Wasan, Daniel H. Palmer et al. · New England Journal of Medicine · 2010 · 4.3K citations · Full text

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology · 2020 · 1.5K citations · Full text

Gastrointestinal Oncology, Medicine, Hepatobiliary Tumor +11

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

John Primrose, Richard Fox, Daniel H. Palmer et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +10

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle et al. · The Lancet Oncology · 2020 · 995 citations · Full text

Gastrointestinal Oncology, Medicine, Biliary Cancer +8

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 986 citations

Placebo Monotherapy, Health Sciences, Gastrointestinal Oncology +15